JK Paper shares in focus after PAT drops 72% YoY to Rs 77 cr in Q4
Shares of
JK Paper
are likely to be in focus on Tuesday following the release of its Q4FY25 earnings report, in which the company reported a sharp 72.3% decline in net profit, falling to Rs 77.05 crore from Rs 278.6 crore in Q4FY24.
According to the earnings data, revenue from operations saw a marginal decline of 1.7%, with Q4FY25 revenue at Rs 1,690 crore, compared to Rs 1,719 crore in the same quarter last year.
Key financial metrics also reflected pressure on margins. EBITDA stood at Rs 241.63 crore, down 42% from Rs 416.44 crore in Q4FY24. As a result, the EBITDA margin contracted by 993 basis points, falling from 24.2% to 14.3% year-on-year.
The board of directors has recommended a dividend of Rs 5 per share for shareholders.
'Profits have been significantly impacted due to a surge in imports at low prices and high wood costs. Despite the adverse market scenario, the company achieved its highest-ever sales of 8.06 LMT during the year and maintained its leadership position across product categories,' said Harsh Pati Singhania, Chairman & Managing Director of JK Paper.
Also read:
Protean eGov Technologies shares plunge 20% after downgrade amid PAN 2.0 project withdrawal
JK Paper share price performance
Over the past year, shares of JK Paper have declined by 6.54%. On a year-to-date (YTD) basis, the fall stands at 18.15%, while the 6-month decline is 13.63%. However, the stock has shown a 20.33% surge over the past 3 months, and a 7.14% gain in the last month.
JK Paper shares
closed flat at Rs 354.25 on the BSE on Tuesday.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
25 minutes ago
- News18
Indian Hockey Players To Get A Monthly Stipend From Sports Ministry
Last Updated: Indian hockey players selected for national camps will receive a Rs 25,000 monthly allowance. The decision, costing Rs 20 lakh per month, was approved by the sports ministry. For the first time, Indian hockey players selected for the men's and women's national camps will receive a Rs 25,000 monthly out-of-pocket allowance, a decision sanctioned by the sports ministry after consistent requests from the sport's governing body. Eighty players (40 men and 40 women) are set to benefit from this allowance, which is extended to athletes in the developmental group of the Target Olympic Podium Scheme. The decision was made during the Mission Olympic Cell's monthly meeting on Thursday. This allowance will cost the government Rs 20 lakh per month, while core group athletes receive Rs 50,000 per month. 'The allowance was being requested by Hockey India for some time, and we have decided to accept the demand. The players have performed reasonably well, and it is on merit," Sports Minister Mansukh Mandaviya informed reporters in an informal interaction. Hockey India will need to submit a list of players every month to facilitate the disbursement of funds. 'The list will consider form and fitness, and names might change depending on these factors," a sports ministry source explained. Currently, hockey players earn salaries from their respective departments and organisations, although a proposal for a graded contract system by Hockey India has been under consideration for the past few years. Their additional source of income comes from prize money for strong international performances in events like the Olympics and the Asian Games. The men's team has secured two consecutive bronze medals in the 2021 Tokyo Olympics and the subsequent Paris Games last year. The women's team finished fourth in Tokyo but did not qualify for the Paris event. Both teams are currently competing in the FIH Pro League's European leg, where the results have not been particularly encouraging so far. The MOC also approved financial proposals amounting to Rs 4.28 crore during the meeting. A significant portion of the funds — Rs 1.38 crore — will be allocated to tennis players such as Saketh Myneni, Jeevan Nedunchezhiyan, and three women players. 'Several proposals for assistance from para-athletes were also approved. Additionally, a few additions were made to the TOPS developmental group. The core group remains unchanged for now," a Sports Authority of India (SAI) official stated. The ministry has also decided to enhance its talent identification process with an app that will allow talented youngsters to upload their performances for evaluation by regional talent identification panels of the SAI. 'If found promising at first glance, the youngster will be invited to Khelo India Regional Centres where their potential will be assessed. This will broaden our talent identification mechanism, which is currently limited to age group competitions," Mandaviya said. 'It will ensure that we can reach the remotest corners of the country to find promising athletes. This is all part of the National Sports Repository System," he added. With PTI inputs.
Deccan Herald
37 minutes ago
- Deccan Herald
Samsung to launch Galaxy M36 5G next week in India
Thanks to deeper collaboration with Google and Samsung, the Galaxy M36 will support advanced versions of Gemini AI features. It will be priced under Rs 20,000 in India.
India.com
38 minutes ago
- India.com
Meet woman, daughter of India's richest pharma tycoon, she now leads Rs 3950000000000 company, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is daughter of Dilip Shanghvi, a famous Pharma businessman. She is in headlines for her role in Sun Pharma, one of India's biggest pharmaceutical companies. His net worth is around $25 billion and known as India's richest pharma billionaire. He is also among the top 100 richest people in the world. But now, his daughter Vidhi Shanghvi has also started handling his business. Who Is Vidhi Shanghvi? Vidhi Shanghvi is an Executive Director in Sun Pharma. After 13 years of experience, she now leads Sun Pharma's Consumer Healthcare and India Distribution. Sun Pharma was founded by her father, Dilip Shanghvi in 1983. They started making psychiatric drugs and slowly became India's most valuable pharma company, with a market capitalisation of Rs 3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term. Vidhi Shanghvi Educational Background Vidhi graduated from the Wharton School at the University of Pennsylvania. In Sun Pharma, she used her education in marketing and consumer healthcare. She began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She also handled many marketing campaigns. After the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi became the Business Head of the company's Consumer Healthcare Division. She has played a big role in the growth of the products like Revital H and Volini in retail stores, pharmacies, and online platforms in India. She also has expertise in various fields like marketing, brand building, project and alliance management, and distribution. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform gives free, holistic mental health solutions to individuals for their mental well-being.
